ESMO 2024-话题@MedSci

#ESMO 2024#

0篇内容 | 169人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2226746, encodeId=959e2226e46a3, content=<a href='/topic/show?id=f07d529e6ca' target=_blank style='color:#2F92EE;'>#恶病质#</a> <a href='/topic/show?id=b6b011e87899' target=_blank style='color:#2F92EE;'>#ESMO 2024#</a> <a href='/topic/show?id=e49611930039' target=_blank style='color:#2F92EE;'>#ponsegromab#</a>, objectTitle=让癌症患者“胖起来”！NEJM：创新靶向疗法解决癌症重要“死因”, objectType=article, longId=843916, objectId=94f8843916b0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240920/1726797596079_8538692.jpg, objectUrl=/article/show_article.do?id=94f8843916b0, replyNumber=0, likeNumber=5, createdTime=昨天, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=94f8843916b0, moduleTitle=让癌症患者“胖起来”！NEJM：创新靶向疗法解决癌症重要“死因”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94f8843916b0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226579, encodeId=94c922265e9db, content=<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=b6b011e87899' target=_blank style='color:#2F92EE;'>#ESMO 2024#</a>, objectTitle=2024ESMO | 新型B7H3抗体偶联药物初次亮相即创多个瘤肿后线疗效新高：张力、赵洪云教授团队口头汇报YL-201初步结果, objectType=article, longId=843769, objectId=3cce843e6950, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240708/1720419680717_92910.jpg, objectUrl=/article/show_article.do?id=3cce843e6950, replyNumber=0, likeNumber=4, createdTime=2024-09-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3cce843e6950, moduleTitle=2024ESMO | 新型B7H3抗体偶联药物初次亮相即创多个瘤肿后线疗效新高：张力、赵洪云教授团队口头汇报YL-201初步结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cce843e6950)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226385, encodeId=e94322263854c, content=<a href='/topic/show?id=735a81364b7' target=_blank style='color:#2F92EE;'>#肝细胞癌#</a> <a href='/topic/show?id=185911139962' target=_blank style='color:#2F92EE;'>#QL1706#</a> <a href='/topic/show?id=b6b011e87899' target=_blank style='color:#2F92EE;'>#ESMO 2024#</a>, objectTitle=疾病控制率高达87.1%，新型双抗“双管齐下”一线治肝癌 | ESMO 2024, objectType=article, longId=843794, objectId=381c843e9440, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240627/1719493607463_8538692.png, objectUrl=/article/show_article.do?id=381c843e9440, replyNumber=0, likeNumber=6, createdTime=2024-09-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=381c843e9440, moduleTitle=疾病控制率高达87.1%，新型双抗“双管齐下”一线治肝癌 | ESMO 2024, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=381c843e9440)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226386, encodeId=d2562226386e5, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=635c8513167' target=_blank style='color:#2F92EE;'>#脑转移#</a> <a href='/topic/show?id=b6b011e87899' target=_blank style='color:#2F92EE;'>#ESMO 2024#</a>, objectTitle=62%乳腺癌脑转移患者，12个月病情未进展！重磅ADC治疗再添新证| ESMO 2024, objectType=article, longId=843800, objectId=7ad284380011, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240711/1720668737938_5579292.png, objectUrl=/article/show_article.do?id=7ad284380011, replyNumber=0, likeNumber=8, createdTime=2024-09-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7ad284380011, moduleTitle=62%乳腺癌脑转移患者，12个月病情未进展！重磅ADC治疗再添新证| ESMO 2024, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ad284380011)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226046, encodeId=9393222604644, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=635c8513167' target=_blank style='color:#2F92EE;'>#脑转移#</a> <a href='/topic/show?id=b6b011e87899' target=_blank style='color:#2F92EE;'>#ESMO 2024#</a>, objectTitle=肺癌脑转移客观缓解率提升近10倍！多个结局指标均明显改善 | ESMO 2024, objectType=article, longId=843385, objectId=66c384338533, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240906/1725599728293_8538692.jpg, objectUrl=/article/show_article.do?id=66c384338533, replyNumber=0, likeNumber=0, createdTime=2024-09-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=66c384338533, moduleTitle=肺癌脑转移客观缓解率提升近10倍！多个结局指标均明显改善 | ESMO 2024, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66c384338533)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226049, encodeId=770b22260496f, content=<a href='/topic/show?id=adf23354483' target=_blank style='color:#2F92EE;'>#化疗#</a> <a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=b6b011e87899' target=_blank style='color:#2F92EE;'>#ESMO 2024#</a>, objectTitle=5年总生存率100%！早期乳腺癌或有望豁免化疗 | ESMO 2024, objectType=article, longId=843445, objectId=7479843445c2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240904/1725441132704_8538692.jpg, objectUrl=/article/show_article.do?id=7479843445c2, replyNumber=0, likeNumber=11, createdTime=2024-09-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7479843445c2, moduleTitle=5年总生存率100%！早期乳腺癌或有望豁免化疗 | ESMO 2024, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7479843445c2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226135, encodeId=6410222613595, content=<a href='/topic/show?id=3263e877271' target=_blank style='color:#2F92EE;'>#结肠癌#</a> <a href='/topic/show?id=1a5a58e00ad' target=_blank style='color:#2F92EE;'>#新辅助治疗#</a> <a href='/topic/show?id=b6b011e87899' target=_blank style='color:#2F92EE;'>#ESMO 2024#</a> <a href='/topic/show?id=a1171191640a' target=_blank style='color:#2F92EE;'>#错配修复功能缺陷#</a>, objectTitle=3年无病生存率达100%！新辅助治疗带来新希望 | ESMO 2024, objectType=article, longId=843570, objectId=07408435e05f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240812/1723427795598_8538692.png, objectUrl=/article/show_article.do?id=07408435e05f, replyNumber=0, likeNumber=0, createdTime=2024-09-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=07408435e05f, moduleTitle=3年无病生存率达100%！新辅助治疗带来新希望 | ESMO 2024, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07408435e05f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226302, encodeId=7fd72226302cb, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a> <a href='/topic/show?id=b6b011e87899' target=_blank style='color:#2F92EE;'>#ESMO 2024#</a>, objectTitle=疾病进展或死亡风险降低45%！一线治疗肺癌，双重免疫疗法联合化疗奏效 | ESMO 2024, objectType=article, longId=843634, objectId=fca184363450, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240708/1720420953692_92910.png, objectUrl=/article/show_article.do?id=fca184363450, replyNumber=0, likeNumber=8, createdTime=2024-09-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=fca184363450, moduleTitle=疾病进展或死亡风险降低45%！一线治疗肺癌，双重免疫疗法联合化疗奏效 | ESMO 2024, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fca184363450)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226306, encodeId=df9e2226306e1, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a> <a href='/topic/show?id=b6b011e87899' target=_blank style='color:#2F92EE;'>#ESMO 2024#</a>, objectTitle=不用化疗，近50%患者癌细胞完全消失！“双免疫”疗法为“最毒乳腺癌”治疗带来新方向 | ESMO 2024, objectType=article, longId=843684, objectId=736084368485, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240712/1720773023306_92910.jpg, objectUrl=/article/show_article.do?id=736084368485, replyNumber=0, likeNumber=12, createdTime=2024-09-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=736084368485, moduleTitle=不用化疗，近50%患者癌细胞完全消失！“双免疫”疗法为“最毒乳腺癌”治疗带来新方向 | ESMO 2024, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=736084368485)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2225615, encodeId=039f222561540, content=<a href='/topic/show?id=41e019635b' target=_blank style='color:#2F92EE;'>#ADC药物#</a> <a href='/topic/show?id=b6b011e87899' target=_blank style='color:#2F92EE;'>#ESMO 2024#</a> <a href='/topic/show?id=5c1b1190412e' target=_blank style='color:#2F92EE;'>#ESG401#</a> <a href='/topic/show?id=0cdf11904247' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌伴脑转移#</a>, objectTitle=ESMO 2024 | 专访马飞教授：TROP2 新型ADC药物！ESG401在HER2阴性乳腺癌伴脑转移患者中展现出突破性疗效, objectType=article, longId=843183, objectId=49df843183f4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240913/1726206407330_92910.png, objectUrl=/article/show_article.do?id=49df843183f4, replyNumber=0, likeNumber=11, createdTime=2024-09-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=49df843183f4, moduleTitle=ESMO 2024 | 专访马飞教授：TROP2 新型ADC药物！ESG401在HER2阴性乳腺癌伴脑转移患者中展现出突破性疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49df843183f4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2225594, encodeId=a183222559439, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=37e863495b0' target=_blank style='color:#2F92EE;'>#母乳喂养#</a> <a href='/topic/show?id=b6b011e87899' target=_blank style='color:#2F92EE;'>#ESMO 2024#</a>, objectTitle=ESMO 2024 ：两项研究首次证明乳腺癌术后母乳喂养是安全的, objectType=article, longId=843072, objectId=9e5e8430e2d3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240913/1726193745184_8624274.png, objectUrl=/article/show_article.do?id=9e5e8430e2d3, replyNumber=0, likeNumber=17, createdTime=2024-09-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9e5e8430e2d3, moduleTitle=ESMO 2024 ：两项研究首次证明乳腺癌术后母乳喂养是安全的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e5e8430e2d3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2220100, encodeId=52cc22201007b, content=<a href='/topic/show?id=b6b011e87899' target=_blank style='color:#2F92EE;'>#ESMO 2024#</a>, objectTitle=ESMO 2024 | 中国肿瘤之声：30+项口头报告闪耀国际舞台, objectType=article, longId=839038, objectId=8d1b839038ad, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240809/7c0422bf2ab5430a95dca34d1a30a4a1-4147WkiokbHk.jpg, objectUrl=/article/show_article.do?id=8d1b839038ad, replyNumber=0, likeNumber=39, createdTime=2024-08-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8d1b839038ad, moduleTitle=ESMO 2024 | 中国肿瘤之声：30+项口头报告闪耀国际舞台, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d1b839038ad)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯管理员

ESMO 2024

2024-08-14发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#恶病质# #ESMO 2024# #ponsegromab#

让癌症患者“胖起来”！NEJM：创新靶向疗法解决癌症重要“死因”

昨天发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#抗体偶联药物# #ESMO 2024#

2024ESMO | 新型B7H3抗体偶联药物初次亮相即创多个瘤肿后线疗效新高：张力、赵洪云教授团队口头汇报YL-201初步结果

2024-09-19发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肝细胞癌# #QL1706# #ESMO 2024#

疾病控制率高达87.1%，新型双抗“双管齐下”一线治肝癌 | ESMO 2024

2024-09-18发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #脑转移# #ESMO 2024#

62%乳腺癌脑转移患者，12个月病情未进展！重磅ADC治疗再添新证| ESMO 2024

2024-09-18发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肺癌# #脑转移# #ESMO 2024#

肺癌脑转移客观缓解率提升近10倍！多个结局指标均明显改善 | ESMO 2024

2024-09-16发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#化疗# #乳腺癌# #ESMO 2024#

5年总生存率100%！早期乳腺癌或有望豁免化疗 | ESMO 2024

2024-09-16发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#结肠癌# #新辅助治疗# #ESMO 2024# #错配修复功能缺陷#

3年无病生存率达100%！新辅助治疗带来新希望 | ESMO 2024

2024-09-16发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#NSCLC# #免疫治疗# #ESMO 2024#

疾病进展或死亡风险降低45%！一线治疗肺癌，双重免疫疗法联合化疗奏效 | ESMO 2024

2024-09-18发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #免疫治疗# #ESMO 2024#

不用化疗，近50%患者癌细胞完全消失！“双免疫”疗法为“最毒乳腺癌”治疗带来新方向 | ESMO 2024

2024-09-18发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#ADC药物# #ESMO 2024# #ESG401# #HER2阴性乳腺癌伴脑转移#

ESMO 2024 | 专访马飞教授：TROP2 新型ADC药物！ESG401在HER2阴性乳腺癌伴脑转移患者中展现出突破性疗效

2024-09-13发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #母乳喂养# #ESMO 2024#

ESMO 2024 ：两项研究首次证明乳腺癌术后母乳喂养是安全的

2024-09-13发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#ESMO 2024#

ESMO 2024 | 中国肿瘤之声：30+项口头报告闪耀国际舞台

2024-08-14发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务